GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Pretax Margin %

Sino Biopharmaceutical (HKSE:01177) Pretax Margin % : 22.77% (As of Jun. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Sino Biopharmaceutical's Pre-Tax Income for the six months ended in Jun. 2024 was HK$3,891 Mil. Sino Biopharmaceutical's Revenue for the six months ended in Jun. 2024 was HK$17,089 Mil. Therefore, Sino Biopharmaceutical's pretax margin for the quarter that ended in Jun. 2024 was 22.77%.

The historical rank and industry rank for Sino Biopharmaceutical's Pretax Margin % or its related term are showing as below:

HKSE:01177' s Pretax Margin % Range Over the Past 10 Years
Min: 20.04   Med: 23.57   Max: 69.14
Current: 21.47


HKSE:01177's Pretax Margin % is ranked better than
89.34% of 1013 companies
in the Biotechnology industry
Industry Median: -148.6 vs HKSE:01177: 21.47

Sino Biopharmaceutical Pretax Margin % Historical Data

The historical data trend for Sino Biopharmaceutical's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Pretax Margin % Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.48 21.20 69.14 20.04 20.65

Sino Biopharmaceutical Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.71 13.48 21.38 19.77 22.77

Competitive Comparison of Sino Biopharmaceutical's Pretax Margin %

For the Biotechnology subindustry, Sino Biopharmaceutical's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Pretax Margin % falls into.



Sino Biopharmaceutical Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Sino Biopharmaceutical's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=5917.241/28656.36
=20.65 %

Sino Biopharmaceutical's Pretax Margin for the quarter that ended in Jun. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=3890.645/17089.485
=22.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biopharmaceutical  (HKSE:01177) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Sino Biopharmaceutical Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.
Executives
Tse Eric S Y 2101 Beneficial owner
Tse Ping 2101 Beneficial owner
Cheng Cheung Ling 2101 Beneficial owner
True Merit Global Limited 2101 Beneficial owner
Tse Theresa Y Y 2101 Beneficial owner
Thousand Eagles Limited 2101 Beneficial owner
France Investment (china 1) Group Limited 2101 Beneficial owner
Remarkable Industries Limited 2101 Beneficial owner
Validated Profits Limited 2101 Beneficial owner

Sino Biopharmaceutical Headlines

No Headlines